Gilead to buy immuno-oncology firm Forty Seven for $4.9bn

Gilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers to its research pipeline.

NICE backs Celgene’s Revlimid for chemo-free lymphoma therap...

Lilly's Cyramza closer to first-line lung cancer use after O...

NICE rejects Roche's Polivy combination in advanced lymphoma

England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with a form of advanced lymphoma, NICE has said in first draft g

Roche hops on Bicycle’s drug discovery platform for cancer

GSK begins cancer cell therapy tie-up with Immatics

Cancer biotech Immatics has begun a collaboration with GlaxoSmithKline to develop novel therapies built around its T-cell-based technology.